Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;36(2):588-590.
doi: 10.1038/s41375-021-01418-8. Epub 2021 Sep 20.

Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas

Francesco Marchesi  1 , Fulvia Pimpinelli  2 , Diana Giannarelli  3 , Livia Ronchetti  4 , Elena Papa  5 , Paolo Falcucci  5 , Martina Pontone  2 , Enea Gino Di Domenico  2 , Simona di Martino  6 , Valentina Laquintana  6 , Chiara Mandoj  7 , Laura Conti  7 , Iole Cordone  7 , Antonia La Malfa  8 , Caterina Viggiani  5 , Daniela Renzi  5 , Francesca Palombi  5 , Atelda Romano  5 , Francesco Pisani  5 , Svitlana Gumenyuk  5 , Ornella Di Bella  9 , Branka Vujovic  9 , Aldo Morrone  10 , Gennaro Ciliberto  11 , Fabrizio Ensoli  2 , Andrea Mengarelli  5
Affiliations

Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas

Francesco Marchesi et al. Leukemia. 2022 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. IgG geometric mean concentrations on TP0, TP1, TP2, and TP3 in the cohorts, AU/mL.
TP0 is day of 1st dose, TP1 is day of 2nd dose (3rd week after 1st dose), TP2 is 5th week after 1st dose, TP3 is 12th week after 1st dose. To evaluate the effect of the second dose of vaccine and of IgG decay kinetics in the groups, the Wilcoxon test was used for comparing geometric mean concentration (GMC) between TP1, TP2, and TP3.
See this image and copyright information in PMC

References

    1. Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165–73. doi: 10.1182/blood.2021011568. - DOI - PMC - PubMed
    1. Roeker LE, Knorr DA, Thompson MC, Nivar M, Lebowitz S, Peters N, et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia. 2021 May 13:1–3. 10.1038/s41375-021-01270-w. - PMC - PubMed
    1. Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, et al. Fifth-week-immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single Institution. J Hematol Oncol. 2021;14:81. doi: 10.1186/s13045-021-01090-6. - DOI - PMC - PubMed
    1. Perry C, Luttwak E, Balaban R, Shefer G, Morales MM, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021;5:3053–61. doi: 10.1182/bloodadvances.2021005094. - DOI - PMC - PubMed
    1. Gurion R, Rozovski U, Itchaki G, Gafter-Gvili A, Leibovitch C, Raanani P, et al. Humoral serologic response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies. Haematologica. 2021 Jul 29. 10.3324/haematol.2021.279216. - PMC - PubMed

Publication types